Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rna
AssigneeDicerna Pharmaceuticals, Inc.
InventorsBob D. BROWN, Henryk T. Dudek
Life of this patent
Estimating the term…
Abstract
This invention relates to compounds, compositions, and methods useful for reducing α-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Claims21
1-68. (canceled)
A method for treating or preventing a liver or lung disease or disorder in a subject comprising administering to the subject a double stranded nucleic acid (dsNA) comprising first and second nucleic acid strands, wherein the first strand is 36 nucleotides in length and the second strand is 22 nucleotides in length, wherein the second strand is complementary to at least 19 contiguous nucleotides of the α-1 antitrypsin target mRNA and has a sequence of at least 19 consecutive nucleotides of SEQ ID NO:
- 358, and wherein said liver disease or disorder is selected from the group consisting of chronic liver disease, liver inflammation, cirrhosis, liver fibrosis and hepatocellular carcinoma, and said lung disease or disorder is selected from the group consisting of emphysema, COPD (chronic obstructive pulmonary disease), and cirrhosis.
A method for treating or preventing a liver or lung disease or disorder in a subject, wherein said liver disease or disorder is selected from the group consisting of chronic liver disease, liver inflammation, cirrhosis, liver fibrosis and hepatocellular carcinoma, and said lung disease or disorder is selected from the group consisting of emphysema, COPD (chronic obstructive pulmonary disease), and cirrhosis, the method comprising administering to the subject a double stranded nucleic acid (dsNA) comprising first and second nucleic acid strands, wherein said first strand is 15-53 nucleotides in length and said second strand is 19-35 nucleotides in length, wherein said second strand is complementary to at least 19 contiguous nucleotides of the α-1 antitrypsin target mRNA and has a sequence of at least 19 consecutive nucleotides of SEQ ID NO:
- 358, wherein said dsNA reduces α-1 antitrypsin target mRNA expression when introduced into a mammalian cell, and wherein said second strand comprises a modification pattern selected from the following:
- AS-M1 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M2 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M3 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M4 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M5 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M6 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M7 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M8 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M9 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M10 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M11 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M12 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M13 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M14 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M15 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M16 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M17 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M18 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M19 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M20 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M21 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M22 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M24 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M25 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M26 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M27 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M28 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M29 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M30 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M31 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M32 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M34 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M35 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M36 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M37 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M38 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M40 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M41 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M42 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M43 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M44 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M45 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M46 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M47 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M48 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M52 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M54 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M55 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M56 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M57 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M58 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M59 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M60 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M61 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M62 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M63 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M64 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M65 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M66 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M67 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M68 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M69 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M70 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M71 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M72 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M73 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M74 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M75 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M76 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M77 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M78 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M79 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M80 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M81 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M82 3′-XpXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M83 3′-XpXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M84 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M85 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M88 3′-FFFXXXXXXXXXXXXXXXXXXXXFFFF-5′
- AS-M89 3′-XXXXFXXXFXFXXXXXXXXXXXXXXXX-5′
- AS-M90 3′-FFFXFXFXFXFXFXFXFXXXXXXFFFF-5′
- AS-M91 3′-FFFXXXXXXXXXXXXXXXXXXXXXXFF-5′
- AS-M92 3′-XXXXXXFXXXXXFXFXXXXXXXXXXXX-5′
- AS-M93 3′-FFFXFXXXXXXXXXXXXXFXXXXXXXX-5′
- AS-M94 3′-FFFXFXFXXXXXFXFXFXFXXXXFFFF-5′
- AS-M95 3′-FFFXFXFXFXFXFXFXFXXXXXXFFFF-5′
- AS-M96 3′-FFFXFXFXFXFXFXFXFXXXXXXFFFpF-5′
- AS-M210 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M1* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M2* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M3* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M4* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M5* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M6* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M7* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M8* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M9* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M10* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M11* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M12* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M13* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M14* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M15* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M16* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M17* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M18* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M19* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M20* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M21* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M22* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M24* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M25* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M26* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M27* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M28* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M29* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M30* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M31* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M32* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M34* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M35* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M36* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M37* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M38* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M40* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M41* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M42* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M43* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M44* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M45* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M46* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M47* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M48* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M52* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M54* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M55* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M56* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M57* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M58* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M59* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M60* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M61* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M62* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M63* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M64* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M65* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M66* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M67* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M68* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M69* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M70* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M71* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M72* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M73* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M74* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M75* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M76* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M77* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M78* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M79* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M80* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M81* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M82* 3′-XpXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M83* 3′-XpXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M84* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M85* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- AS-M88* 3′-XFFXXXXXXXXXXXXXXXXXXXXFFFF-5′
- AS-M89* 3′-XXXXFXXXFXFXXXXXXXXXXXXXXXX-5′
- AS-M90* 3′-XFFXFXFXFXFXFXFXFXXXXXXFFFF-5′
- AS-M91* 3′-XFFXXXXXXXXXXXXXXXXXXXXXXFF-5′
- AS-M92* 3′-XXXXXXFXXXXXFXFXXXXXXXXXXXX-5′
- AS-M93* 3′-XFFXFXXXXXXXXXXXXXFXXXXXXXX-5′
- AS-M94* 3′-XFFXFXFXXXXXFXFXFXFXXXXFFFF-5′
- AS-M95* 3′-XFFXFXFXFXFXFXFXFXXXXXXFFFF-5′
- AS-M96* 3′-XFFXFXFXFXFXFXFXFXXXXXXFFFpF-5′
- AS-M210* 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′
- wherein “X”=RNA, “X”=2′-O-methyl RNA, “F”=2′-Fluoro NA and “p”=Phosphorothioate linkage.
A method for reducing expression of a target α-1 antitrypsin mRNA in a mammal comprising administering to the mammal a double stranded nucleic acid (dsNA) comprising first and second nucleic acid strands, wherein said first strand is 15-53 nucleotides in length and said second strand is 19-35 nucleotides in length, wherein said second strand is complementary to at least 19 contiguous nucleotides of the α-1 antitrypsin target mRNA and has a sequence of at least 19 consecutive nucleotides of SEQ ID NO:
- 358, wherein said dsNA reduces α-1 antitrypsin target mRNA expression when introduced into a mammalian cell.
Dependencies are inferred from the claim text.